Tetracycline antibiotics. This product is a broad-spectrum antibacterial agent. Many Rickettsia, Mycoplasma, Chlamydia, and Spirochete are sensitive to this product. Enterococci are resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, Yersinia, etc. are also sensitive to this product. Due to the widespread use of oxytetracycline and tetracyclines over the years, common clinical pathogens have serious resistance to oxytetracycline, including Gram-positive bacteria such as Staphylococcus and most Gram-negative bacteria. There is cross-resistance between this product and different varieties of tetracycline antibiotics. The mechanism of action of this product is that the drug can specifically bind to the A position of the 30S subunit of the bacterial ribosome, inhibit the growth of the peptide chain and affect the synthesis of bacterial proteins.

This product is an aromatic propionic acid derivative and a non-steroidal anti-inflammatory analgesic. In addition to inhibiting cyclooxygenase, this product also has a certain effect of inhibiting lipoxygenase and reducing bradykinin, thereby reducing the pain sensation at the site of inflammation and injury. Because bradykinin and prostaglandins can cause pain together. Bradykinin can also cause uterine contraction, so this product is used for dysmenorrhea, mainly by inhibiting bradykinin, thereby inhibiting uterine contraction and analgesia to achieve therapeutic effects. This product also has a certain central analgesic effect.

This product is an aromatic propionic acid derivative and a non-steroidal anti-inflammatory analgesic. In addition to inhibiting cyclooxygenase, this product also has a certain effect of inhibiting lipoxygenase and reducing bradykinin, thereby reducing the pain sensation at the site of inflammation and injury. Because bradykinin and prostaglandins can cause pain together. Bradykinin can also cause uterine contraction, so this product is used for dysmenorrhea, mainly by inhibiting bradykinin, thereby inhibiting uterine contraction and analgesia to achieve therapeutic effects. This product also has a certain central analgesic effect.

This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.

This product has a broad-spectrum antimicrobial effect in vitro, including aerobic Gram-negative and Gram-positive bacteria, anaerobes, Rickettsia, spirochetes and Chlamydia. It has bactericidal effects on Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis; it only has antibacterial effects on anaerobic bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Group B hemolytic Streptococcus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhi, Salmonella paratyphi, Shigella, Bacteroides fragilis, etc. Pseudomonas aeruginosa, Acinetobacter, Enterobacter, Serratia marcescens, indole-positive Proteus, methicillin-resistant Staphylococcus and Enterococcus are usually resistant to chloramphenicol. This product is an antibacterial agent that diffuses into bacterial cells and reversibly binds to the 50S subunit of bacterial ribosomes, inhibiting the formation of peptide chains and thus preventing protein synthesis.